Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis
Authors:
Open Access
- 25 March 2020
- journal article
- review article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (3)
Abstract
Background O6-methylguanine-DNA methyltransferase (MGMT) is a specific DNA damage reversal repair protein. The influence of MGMT status on alkylating agent sensitivity in patients with neuroendocrine neoplasms (NENs) is controversial. We conducted a meta-analysis to assess the influence of MGMT status on the therapeutic sensitivity of alkylating agents in patients with NENs. Methods We searched PubMed, EmBase, and Cochrane library public databases through 3 July 2019. The objective response rate (ORR) was the outcome data of interest. Subgroup analysis was performed according based on MGMT methylation and expression of MGMT protein. Results Eleven studies were included in the meta-analysis. The proportion of patients with NENs that achieved an ORR after alkylating agent treatment was higher in the MGMT-deficient group than the non-deficient group (OR: 5.00; 95% CI: 3.04-8.22; p2: 3%). Similar results were noted in the MGMT methylation and MGMT protein expression subgroups. Conclusion Patients with NENs and MGMT methylation or low protein expression had a higher ORR proportion than patients without MGMT methylation or high protein expression. The MGMT status can be used as a biological indicator of the response to alkylating agent treatment in patients with NENs.Keywords
This publication has 34 references indexed in Scilit:
- Meta-analysis of DNA methylation biomarkers in hepatocellular carcinomaOncotarget, 2016
- MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumorsEndocrine-Related Cancer, 2016
- The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors2015
- Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choiceCancer, 2015
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsAnnals of Oncology, 2015
- O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agentsBritish Journal of Cancer, 2015
- Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysisJournal of Neuro-Oncology, 2011
- Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapyCancer, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008